« Return to News | R&D Trends

Immune Design, Sanofi collaborate in allergy research

Wednesday, October 26, 2011 10:39 AM

Immune Design has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

"We are excited to form this relationship with Sanofi," noted IDC CEO Carlos Paya, MD, Ph.D.  "The application of next-generation TLR-4 agonists able to shape the immune response in allergic disease has enormous therapeutic potential.  Our initial collaboration has the strong possibility to lead to a broader development focused partnership with Sanofi in the near future."

Under the agreement, IDC will provide access to the GLA technology, allowing Sanofi the ability to evaluate the biological and immunological properties of this TLR-4 agonist in vitro and in allergy disease models, and will be granted an option to select lead candidates for further development. The terms have not been disclosed.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.